Aged Garlic Extract Reduces Low Attenuation Plaque in Coronary Arteries of Patients with Metabolic Syndrome in a Prospective Randomized Double-Blind Study

Suguru Matsumoto, Rine Nakanishi, Dong Li, Anas Alani, Panteha Rezaeian, Sach Prabhuk, Jey Abraham, Michael A Fahmy, Christopher Dailing, Ferdinand Flores, Sajad Hamal, Alexander Broersen, Pieter H Kitslaar, and Matthew J Budoff

Abstract

Background: Although several previous studies have demonstrated that aged garlic extract (AGE) inhibits the progression of coronary artery calcification, its effect on noncalcified plaque (NCP) has been unclear.

Objective: This study investigated whether AGE reduces coronary plaque volume measured by cardiac computed tomography angiography (CCTA) in patients with metabolic syndrome (MetS).

Methods: Fifty-five patients with MetS (mean ± SD age: 58.7 ± 6.7 y; 71% men) were prospectively assigned to consume 2400 mg AGE/d (27 patients) or placebo (28 patients) orally. Both groups underwent CCTA at baseline and follow-up 354 ± 41 d apart. Coronary plaque volume, including total plaque volume (TPV), dense calcium (DC), NCP, and low-attenuation plaque (LAP), were measured based upon predefined intensity cutoff values. Multivariable linear regression analysis, adjusted for age, gender, number of risk factors, hyperlipidemia medications, history of coronary artery disease, scan interval time, and baseline TPV, was performed to examine whether AGE affected each plaque change.

Results: The %LAP change was significantly reduced in the AGE group compared with the placebo group (−1.5% ± 2.3% compared with 2.2% ± 2.0%, P = 0.0049). In contrast, no difference was observed in %TPV change (0.3% ± 3.3% compared with 1.6% ± 3.0%, P = 0.13), %NCP change (2.2% ± 3.3% compared with 1.4% ± 2.9%, P = 0.14), and %DC change (0.2% ± 1.4% compared with 0.2% ± 1.7%, P = 0.99). Multivariable linear regression analysis found a beneficial effect of AGE on %LAP regression (β: −1.61; 95% CI: −2.79, −0.43; P = 0.008).

Conclusions: This study indicates that the %LAP change was significantly greater in the AGE group than in the placebo group.

Further studies are needed to evaluate whether AGE has the ability to stabilize vulnerable plaque and decrease adverse cardiovascular events. This trial was registered at clinicaltrials.gov as NCT01534910. J Nutr 2016;146(Suppl):427S–32S.

Keywords: garlic, atherosclerosis, progression, cardiac CT, randomized trial

Introduction

Metabolic syndrome (MetS) is a constellation of metabolic abnormalities that includes features of obesity, hypertension, hyperlipidemia, and impaired glucose tolerance. Approximately 20% of the US population is diagnosed with MetS. MetS is associated with subclinical cardiovascular disease; nearly one-half of patients diagnosed with coronary artery disease (CAD) are also diagnosed with MetS. For this condition, the Adult Treatment Panel III recommends adopting a healthy lifestyle and also effectively managing each cardiovascular disease risk factor through the use of clinically established medications such as aspirin, angiotensin-converting enzyme inhibitors, and statins. Furthermore, dietary therapy also has an important role for prevention of the progression atherosclerosis. Recent studies have shown that diet therapy such as the Mediterranean diet has a beneficial effect on cardiovascular disease. In addition, dietary supplements such as garlic extract have been known to have a positive effect on cardiovascular disease risk factors, including blood pressure, cholesterol, and endothelial function. Our group has shown through the use of noncontrast cardiac computed tomography (CT) that aged garlic extract (AGE) helped slow progression of coronary artery calcium.
only detection of coronary artery anatomic stenosis but also coronary plaque composition with a high degree of diagnostic accuracy. The diagnostic accuracy and feasibility of this technique is illustrated in many previous studies (10–12). Although previous studies have demonstrated that noncalcified plaque (NCP) has an important role in acute coronary events (13, 14), the effect of AGE on NCP is unclear. This current study investigates whether AGE reduces plaque volume, including NCP measured by CCTA in patients with MetS.

Methods

Study population and randomization. The present study was a placebo-controlled double-blind study (NCT01534910). Seventy-two patients were enrolled and underwent CCTA. The Investigational Review Board of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center approved this research project. All patients signed informed written consent forms after careful explanation and review of the protocol. Eligible participants were 40–75 y of age who had at least 2 components of MetS as defined by the Adult Treatment Panel III Clinical Identification of MetS (including impaired fasting glucose >110 mg/dL, treated hypertension or systolic blood pressure >130 mm Hg or diastolic blood pressure >85 mm Hg, TGs >150 mg/dL, HDL cholesterol <35 mg/dL for men or <40 mg/dL for women, abdominal obesity as defined as waist circumference >40 inches (1.02 meters) for men or >35 inches (0.89 meters) for women). Glucose and cholesterol were assayed from serum with the use of an Abbott autoanalyzer.

Participants all had a 10 y Framingham risk of CAD of 6–20%. Patients were assigned at a 1:1 ratio to receive 2400 mg AGEEd or a placebo. The intended duration of administration for the study group was 52 wk.

Exclusion criteria. We excluded patients with known hypersensitivity to garlic therapy, renal impairment (serum creatinine >1.4 mg/dL), New York Heart Association Functional Classification II–IV heart failure, TGs >400 mg/dL at first visit, documented current diabetes or taking any antidiabetic drug, current tobacco use, or who were currently enrolled in another placebo-controlled trial.

Aged garlic extract. As previously demonstrated (8, 9), the AGE (Kyolic), provided by Wakunaga of America, was formulated by soaking sliced raw garlic in aqueous ethanol for up to 20 mo at room temperature. The extract was then filtered and concentrated at low temperature. The AGE used in this trial contained 305 g extracted solids/L. The finished product used in this clinical study was commercially available.

Clinical analyses. Blood samples were collected after a 12 h fast. Sample were stored at ~70°C and analyzed for serum glucose and a lipid profile, including serum LDL cholesterol, HDL cholesterol, and TGs, with the use of automated diagnostic equipment (DYZ Laboratories).

Data acquisition. A 64-slice multidetector CT scanner (General Electric Healthcare) was used to acquire images, as previously reported (15). Sublingual nitroglycerin or nitroglycerin spray 0.4 mg was administered before the scan. Prescan beta-blockers were also given to achieve a resting heart rate of <60 beats/min. The following imaging and reconstruction variables were applied: collimation 64 × 0.625 mm, tube voltage 100–120 kV, tube current 350–780 milliamperes. Prospective studies were performed if the heart rate was sufficiently controlled (<60 beats/min) with images acquired from 65% to 75% of the R–R interval. An iodinated contrast material (350 g/L; Omnipaque, General Electric Healthcare) was injected intravenously, depending on expected scan time, which was detected by a timing bolus technique and followed by a 50 mL saline flush.

Coronary plaque assessment. All coronary images were transferred to the workstation with the use of semiautomated plaque analysis software (QAngioCT Research Edition Version 2.0.5, Medis Medical Imaging Systems). Studies were blinded for AGE or placebo use, and expert readers assessed the coronary arteries.

The protocol for quantitative plaque assessment has been published in previous studies (10, 12). Vessel diameters ≥1.5 mm were evaluated and assessed based on a Society of Cardiovascular Computed Tomography 17-segment coronary artery model (16). We excluded those segments that could not be evaluated because of severe artifacts on either of the serial scans. Any segments with stents were also omitted because plaque cannot be assessed in stents with the use of CCTA. Coronary plaque volume, including total plaque volume (TPV), fibrotic, fibro-fatty tissue, low-attenuation plaque (LAP), and dense calcium (DC) was calculated by the Hounsfield unit threshold (10) at baseline and follow-up. The Hounsfield unit threshold was changed dynamically by the software based on the theory that plaque attenuation values are affected by luminal contrast densities (17). These thresholds are based upon studies that compare CCTA with virtual histology by intravascular ultrasound (10). Fibrotic, fibro-fatty tissue, and NC were summed and further classified as NCP (18). Percentage TPV, LAP volume, NCP volume, and DC volume were defined as TPV, LAP, NCP, or DC divided by total vessel volume, which follows intravascular ultrasound–like variables (19). The change (follow-up–baseline) in each value from baseline was calculated for each patient.

Statistical analysis. Continuous variables were expressed as means ± SDs. Comparisons of all parameters between the AGE and placebo groups were made with the use of Student’s t test. Categoric variables were expressed as counts and percentages and a χ² test was used for comparisons between the placebo and AGE groups. To correct for differences in baseline values, we performed multiple linear regression analysis. By multivariable linear regression analysis, we examined
whether AGE is associated with plaque regression of %LAP, %TAP, %NCP, and %DC, after adjusting for age, gender, number of risk factors, hyperlipidemia medications, history of known CAD, scan interval time, and baseline %TPV. A value of \( P < 0.05 \) was considered statistically significant. All statistical analyses were performed with the use of SAS software (version 9.3).

**Results**

**Baseline characteristics.** From June 2012 through December 2012, 72 patients were enrolled and randomly assigned to placebo or AGE groups. Patients were maintained on current medications such as aspirin, hypertensive, or hyperlipidemia medication, and did not change medications during the study period. Participants were followed for a mean \( \pm SD \) of 354 \( \pm 41 \) d (range: 250–461 d). As of October 2013, 15 patients were unable to undergo a follow-up visit. We also excluded 2 patients with coronary artery bypass graft from the analysis because of imaging artifacts from excessive DC in their vessels. Ultimately, this gave us a total of 587 segments from 55 patients (mean 11 \( \pm \) 3 segments; range: 2–15 segments per patient) to analyze for this study (Figure 1).

**Plaque characteristics at baseline and follow-up, and the change among placebo and AGE groups.** The baseline data at entry into this study are presented in Table 1. The 2 groups had similar demographic characteristics. However, baseline %TPV and %DC were significantly higher in the placebo group than in the AGE group, whereas %LAP was lower in the placebo group (Table 2). The change in value of each plaque over 1 y in the placebo and AGE groups is shown in Table 2. The %LAP change was significantly reduced in the AGE group compared with the placebo group. However, no significant difference was seen in %TPV, %NCP, or %DC. A CCTA case example is presented in Figure 2. By multivariable linear regression analysis adjusting for age, gender, number of risk factors, hyperlipidemia medications, history of known CAD, scan interval time, and baseline %TPV, a beneficial effect from AGE was observed with respect to LAP regression, but not for %TPV, %NCP, or %DC (Table 2).

**Discussion**

The current study demonstrates that, in patients with MetS, %LAP change was significantly greater in the AGE group than in the placebo group after 1 y of treatment. This result is consistent with the previous study that showed the beneficial effect of AGE on atherosclerosis.

In general, atherosclerosis starts with the accumulation of oxidized LDL within the intima. Lipoprotein attracts macrophages, which are transformed into foam cells after phagocytosing these pools of lipids. These foam cells eventually undergo necrosis, which forms a necrotic core within the intima. In addition, pathologic studies with the use of invasive coronary angiography have shown that the culprit lesion of acute coronary syndrome likely has a lipid-rich necrotic core, which is covered by a thin fibrous cap (14, 20).

CCTA is a noninvasive modality with excellent diagnostic accuracy in identifying the presence, extent, and severity of CAD, as well as coronary plaque characteristics (11, 21).

**TABLE 1** Baseline characteristics of study population

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n = 28)</th>
<th>AGE (n = 27)</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>58.7 ± 6.7</td>
<td>56.8 ± 7.4</td>
<td>0.32</td>
</tr>
<tr>
<td>Male</td>
<td>21 (75.0)</td>
<td>19 (70.4)</td>
<td>0.70</td>
</tr>
<tr>
<td>Hypertension</td>
<td>13 (46.4)</td>
<td>12 (44.4)</td>
<td>0.88</td>
</tr>
<tr>
<td>Taking antihypertensive medicine</td>
<td>9 (32.1)</td>
<td>6 (22.2)</td>
<td>0.41</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>13 (46.4)</td>
<td>9 (33.3)</td>
<td>0.32</td>
</tr>
<tr>
<td>Taking antihyperlipidemia medicine</td>
<td>8 (28.6)</td>
<td>7 (25.9)</td>
<td>0.83</td>
</tr>
<tr>
<td>Family history of CAD</td>
<td>11 (39.3)</td>
<td>7 (25.9)</td>
<td>0.29</td>
</tr>
<tr>
<td>Known CAD</td>
<td>2 (7.1)</td>
<td>0 (0)</td>
<td>0.16</td>
</tr>
<tr>
<td>Scan period, mo</td>
<td>11.7 ± 1.6</td>
<td>11.5 ± 1.1</td>
<td>0.68</td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg</td>
<td>131 ± 2</td>
<td>132 ± 2</td>
<td>0.75</td>
</tr>
<tr>
<td>Diastolic blood pressure, mm Hg</td>
<td>77 ± 2</td>
<td>81 ± 2</td>
<td>0.19</td>
</tr>
<tr>
<td>Serum LDL cholesterol, mg/dL</td>
<td>124 ± 43</td>
<td>131 ± 29</td>
<td>0.55</td>
</tr>
<tr>
<td>Serum HDL cholesterol, mg/dL</td>
<td>58 ± 14</td>
<td>58 ± 18</td>
<td>0.82</td>
</tr>
<tr>
<td>Serum TGs, mg/dL</td>
<td>142 ± 71</td>
<td>139 ± 91</td>
<td>0.91</td>
</tr>
<tr>
<td>Serum glucose, mg/dL</td>
<td>100 ± 3</td>
<td>101 ± 3</td>
<td>0.77</td>
</tr>
<tr>
<td>Framingham risk score, %</td>
<td>17 ± 2</td>
<td>16 ± 2</td>
<td>0.77</td>
</tr>
</tbody>
</table>

1 Values are means ± SDs or n (%). AGE, aged garlic extract; CAD, coronary artery disease.
TABLE 2  Change in each percentage plaque volume after 345 ± 41 d of placebo compared with AGE (2400 mg/d) treatment in adult patients with MetS.

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Baseline</th>
<th>Follow-up</th>
<th>Δ</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Unadjusted model</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adjusted model</td>
<td></td>
</tr>
<tr>
<td>TPV, %</td>
<td>28</td>
<td>30.6 ± 6.5</td>
<td>37.7 ± 6.5</td>
<td>7.1</td>
<td>0 (Ref)</td>
<td>0.06</td>
</tr>
<tr>
<td>AGE</td>
<td>27</td>
<td>31.2 ± 6.5</td>
<td>35.0 ± 6.5</td>
<td>3.8</td>
<td>−1.95 (0.85)</td>
<td>0.08</td>
</tr>
<tr>
<td>NCP, %</td>
<td>28</td>
<td>31.4 ± 3.1</td>
<td>32.6 ± 3.8</td>
<td>1.2</td>
<td>0 (Ref)</td>
<td>0.09</td>
</tr>
<tr>
<td>Placebo</td>
<td>27</td>
<td>30.8 ± 4.1</td>
<td>30.8 ± 3.8</td>
<td>0.0</td>
<td>−1.45 (0.85)</td>
<td>0.22</td>
</tr>
<tr>
<td>LACP, %</td>
<td>28</td>
<td>3.6 ± 2.2</td>
<td>3.2 ± 1.7</td>
<td>0.4</td>
<td>0 (Ref)</td>
<td>0.008</td>
</tr>
<tr>
<td>AGE</td>
<td>27</td>
<td>5.0 ± 2.7</td>
<td>3.5 ± 2.1</td>
<td>−1.5</td>
<td>−1.81 (0.60)</td>
<td>−0.43</td>
</tr>
<tr>
<td>NCP, %</td>
<td>28</td>
<td>4.9 ± 6.6</td>
<td>5.1 ± 6.4</td>
<td>0.2</td>
<td>0 (Ref)</td>
<td>0.92</td>
</tr>
<tr>
<td>Placebo</td>
<td>27</td>
<td>1.3 ± 2.4</td>
<td>1.5 ± 1.8</td>
<td>0.2</td>
<td>−0.04 (0.44)</td>
<td>−0.90</td>
</tr>
</tbody>
</table>

Values are means ± SDs. Models were adjusted for age, gender, number of risk factors, antihyperlipidemia medications, known CAD, scan interval, and baseline %TPV. 1Different from placebo. 2P < 0.05; 3P < 0.01. AGE, aged garlic extract; CAD, coronary artery disease; DC, dense calcium; LACP, low-attenuation plaque; MetS, metabolic syndrome; NCP, noncalcified plaque; TPV, total plaque volume.

Motoyama et al. (13) used CCTA to define plaque features that likely lead to acute coronary syndrome, such as positively dilated coronary arteries, voluminous plaque, and large LAP content (necrotic core). Although statins have been shown to reduce LAP in previous findings (22, 23), this study indicates that AGE has the ability to stabilize atherosclerosis by reducing the amount of LAP in a manner similar to that of statin therapy.

The mechanism by which garlic affects the atherosclerotic process, however, still remains unclear. Nonetheless, previous reports support several complex mechanisms of garlic metabolites that contribute to the suppression of atherosclerosis. For example, a garlic supplement with high concentrations of S-alloy cysteine have been shown to have a cholesterol-lowering effect (24, 25). γ-Glutamylcysteine—a component of garlic—also has the ability to decrease blood pressure by modulating nitric oxide and endothelia synthesis (26, 27). Furthermore, the anti-inflammatory effect of garlic was also reported. Specifically, AGE therapy led to a decrease in CD36 expression on foam cells and oxidized LDL uptake in macrophages (28). Our laboratory previously has shown the possibility that AGE has an antioxidative effect through the observation of autoantibodies to malondialdehyde LDL and oxidized phospholipids on

FIGURE 2  Representative example automated plaque quantification analysis. The lumen border contours and vessel wall borders are assessed and eccentric noncalcified plaque is observed. CT, computed tomography; VCT, volume computed tomography.
apoipoprotein B-100 particles, which are markers of oxidation (9). This is congruent with previous studies that indicate that garlic has an inhibitory effect on LDL oxidation (29). Together these findings validate that AGE exhibits an antiatherosclerotic effect. Additional research is necessary to examine whether AGE is associated with the reduction of future cardiac events.

**Limitations.** The present study has several limitations. First, this relatively small sample size and short-term follow-up study did not have enough power to show the significant differences in TPV, NCP, and DC. Second, patients were under different therapies. For example, with respect to hyperlipidemia, some patients used varying medications and different doses. Because of our small sample size, a separate analysis by different hyperlipidemia medications was not performed. Third, plaque volume, including %TPV, %LAP, and %DC, was significantly different at baseline between the 2 groups. Therefore, we operated a multivariable linear regression analysis including baseline %TPV (%DC and %LAP were represented by %TPV). Finally, although we evaluated individual plaque volume with the use of semiautomated plaque quantification software, we still cannot exclude the possibility of reading error and variability, especially in the images with excess noise or motion artifact. However, we evaluated 13 randomly selected patients undergoing CCTA in our group to evaluate interobserver variability. We reported excellent interobserver variability in assessing each plaque volume (30).

**Conclusion**

This study indicates that the %LAP change was significantly greater in the AGE group than in the placebo group. Further studies are needed to evaluate whether AGE has the ability to stabilize vulnerable plaque and to decrease adverse cardiovascular events.

**Acknowledgments**

MJB conceived of and designed the study; SP, JA, MAF, FF, and SH generated the clinical data; AA, PR, SP, JA, MAF, CD, FF, and SH collected the patient information; SM, RN, DL, AA, PR, AB, PHK, and MJB analyzed and/or interpreted the data; and SM, RN, AA, and MJB drafted or revised the manuscript. All authors read and approved the final version of the manuscript.

**References**


